NASDAQ:MOLN Molecular Partners (MOLN) Stock Price, News & Analysis → The #1 Biotech Stock to Have on Your Radar in 2024… (From Huge Alerts) (Ad) Free MOLN Stock Alerts $3.88 0.00 (0.00%) (As of 04/24/2024 ET) Add Compare Share Share Today's Range$3.88▼$3.8850-Day Range$3.32▼$4.8452-Week Range$3.32▼$7.32Volume187 shsAverage Volume5,072 shsMarket Capitalization$141.12 millionP/E RatioN/ADividend YieldN/APrice Target$4.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsShort InterestSocial Media Get Molecular Partners alerts: Email Address Molecular Partners MarketRank™ Stock AnalysisAnalyst RatingHold2.00 Rating ScoreUpside/Downside16.0% Upside$4.50 Price TargetShort InterestHealthy0.13% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.25Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.96) to ($1.78) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.66 out of 5 starsMedical Sector842nd out of 909 stocksBiological Products, Except Diagnostic Industry149th out of 156 stocks 2.0 Analyst's Opinion Consensus RatingMolecular Partners has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageMolecular Partners has received no research coverage in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.13% of the outstanding shares of Molecular Partners have been sold short.Short Interest Ratio / Days to CoverMolecular Partners has a short interest ratio ("days to cover") of 9.8.Change versus previous monthShort interest in Molecular Partners has recently decreased by 2.24%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldMolecular Partners does not currently pay a dividend.Dividend GrowthMolecular Partners does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for MOLN. Previous Next 1.8 News and Social Media Coverage News SentimentMolecular Partners has a news sentiment score of 0.25. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.43 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Molecular Partners this week, compared to 0 articles on an average week. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Molecular Partners insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 5.93% of the stock of Molecular Partners is held by insiders.Percentage Held by InstitutionsOnly 26.55% of the stock of Molecular Partners is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Molecular Partners are expected to grow in the coming year, from ($1.96) to ($1.78) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Molecular Partners is -1.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Molecular Partners is -1.83, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMolecular Partners has a P/B Ratio of 0.72. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Huge AlertsThe #1 Biotech Stock to Have on Your Radar in 2024… Revenues exploding, a $18.70 price target, and highly lucrative addressable markets make this one you cannot ignore!Learn more about why Zack’s has a BULLISH nearly $19 price target on BSEM right now! About Molecular Partners Stock (NASDAQ:MOLN)Molecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia. It also develops Switch-DARPin platform, a multispecific cKIT x CD16a x CD47 Switch-DARPin program for targeted and conditional immune cell activation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has license and research collaboration agreements with Novartis Pharma AG to develop DARPin-conjugated radioligand therapies; and collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland.Read More MOLN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MOLN Stock News HeadlinesApril 19, 2024 | globenewswire.comLife Science Cares Launches in SwitzerlandApril 18, 2024 | finance.yahoo.comWe Think Molecular Partners (VTX:MOLN) Needs To Drive Business Growth CarefullyApril 24, 2024 | Traders Agency (Ad)top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.April 17, 2024 | globenewswire.comMolecular Partners Announces All Board Proposals Approved at the Annual General MeetingApril 4, 2024 | bizjournals.comBeyond Benign, MilliporeSigma partner on green chemistryMarch 26, 2024 | globenewswire.comMolecular Partners Publishes Invitation to Annual General Meeting 2024March 21, 2024 | markets.businessinsider.comLeerink Partners Keeps Their Hold Rating on Molecular Partners (MOLN)March 14, 2024 | globenewswire.comMolecular Partners Reports Corporate Highlights From Q4 2023 and Key Financials for Full Year 2023April 24, 2024 | Traders Agency (Ad)top AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligence stock[/lin] is NOT Microsoft, Google, Amazon or Apple. Nope — his research is pointing to a tiny, under-the-radar stock that’s trading for just a few dollars right now… And could soon shoot to the moon, handing early investors a windfall.March 13, 2024 | markets.businessinsider.comMolecular Partners AG (spons. ADRs) hosts conference call for investorsMarch 13, 2024 | finance.yahoo.comThe past three years for Molecular Partners (VTX:MOLN) investors has not been profitableMarch 2, 2024 | uk.investing.comMolecular Partners wins dismissal of securities lawsuitMarch 1, 2024 | globenewswire.comMolecular Partners Announces Dismissal of Class Action LawsuitMarch 1, 2024 | globenewswire.comMolecular Partners To Hold Conference Call to Discuss Fourth Quarter and Full Year 2023 Results and Announces Upcoming Investor PresentationsJanuary 7, 2024 | finance.yahoo.comMolecular Partners Provides Updates at 42nd Annual J.P. Morgan Healthcare ConferenceJanuary 5, 2024 | msn.comMolecular Partners, Orano to collaborate on RDT therapies for cancerDecember 31, 2023 | ca.finance.yahoo.comMolecular Partners AG (6ML0.MU)December 10, 2023 | finance.yahoo.comMolecular Partners Presents Positive Initial Data from First Four Dosing Cohorts of Ongoing Phase 1/2a Trial of MP0533 for Patients with Relapsed/Refractory AML and AML/MDS at ASH Annual MeetingNovember 11, 2023 | morningstar.comMolecular Partners AG ADR MOLNNovember 2, 2023 | finance.yahoo.comMolecular Partners to Present Initial Data from Ongoing Phase 1/2a Trial of MP0533 for Patients with Relapsed/Refractory AML and AML/MDS at the 65th ASH Annual Meeting and ExpositionNovember 1, 2023 | finance.yahoo.comMolecular Partners to Participate in the TD Cowen 7th Annual Fall Oncology Innovation SummitOctober 5, 2023 | finance.yahoo.comShareholders in Molecular Partners (VTX:MOLN) are in the red if they invested five years agoAugust 24, 2023 | finance.yahoo.comMolecular Partners Reports H1 2023 Corporate Highlights and FinancialsJuly 13, 2023 | finance.yahoo.comOwning 32% shares,hedge funds owners seem interested in Molecular Partners AG (VTX:MOLN),June 27, 2023 | finance.yahoo.comMolecular Partners to Present on its Radio DARPin Therapy (RDT) Platform at SNMMI 2023June 27, 2023 | finance.yahoo.comMolecular Partners to Present on its Radio DARPin Therapy (RDT) Platform at SNMMI 2023June 19, 2023 | finance.yahoo.comMolecular Partners to Present at The TD Cowen Radiopharmaceutical Innovation SummitSee More Headlines Receive MOLN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Molecular Partners and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/14/2024Today4/24/2024Next Earnings (Estimated)5/10/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:MOLN CUSIPN/A CIK1745114 Webwww.molecularpartners.com Phone41-44-755-7700FaxN/AEmployees167Year FoundedN/APrice Target and Rating Average Stock Price Target$4.50 High Stock Price Target$4.50 Low Stock Price Target$4.50 Potential Upside/Downside+16.9%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($2.12) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-69,040,000.00 Net Margins-885.11% Pretax Margin-880.66% Return on Equity-31.10% Return on Assets-27.93% Debt Debt-to-Equity RatioN/A Current Ratio13.35 Quick Ratio13.35 Sales & Book Value Annual Sales$7.84 million Price / Sales17.86 Cash FlowN/A Price / Cash FlowN/A Book Value$5.41 per share Price / Book0.71Miscellaneous Outstanding Shares36,370,000Free Float34,212,000Market Cap$140.02 million OptionableNot Optionable Beta0.77 Elon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free Report Key ExecutivesDr. Patrick Amstutz Ph.D. (Age 49)Co-Founder, CEO, Member of Management Board & Director Comp: $725.47kDr. Michael Tobias Stumpp Ph.D. (Age 52)Co-Founder, Executive VP of Projects & Member of Management Board Mr. Robert HendriksSenior VP of FinanceMr. Alexander Zurcher (Age 49)COO & Member of Management Board Ms. Renate Gloggner (Age 54)Executive VP of People & Community and Member of Management Board Mr. Daniel Steiner Ph.D.Senior Vice President of Research & TechnologyMr. Seth D. LewisSenior Vice President of Investor Relations, Communications & StrategyMr. Michael PitznerGeneral Counsel, Compliance Officer, Senior VP Legal & Business DevelopmentDr. Pamela A. Trail Ph.D. (Age 68)Strategic Consultant Ms. Anne Goubier D.V.M.Ph.D., Senior Vice President of Research & Early DevelopmentMore ExecutivesKey CompetitorsDBV TechnologiesNASDAQ:DBVTAgenusNASDAQ:AGENCellectisNASDAQ:CLLSVaxartNASDAQ:VXRTZura BioNASDAQ:ZURAView All Competitors MOLN Stock Analysis - Frequently Asked Questions Should I buy or sell Molecular Partners stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Molecular Partners in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street analysts is that investors should "hold" MOLN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MOLN, but not buy additional shares or sell existing shares. View MOLN analyst ratings or view top-rated stocks. What is Molecular Partners' stock price target for 2024? 1 brokers have issued 12 month price targets for Molecular Partners' stock. Their MOLN share price targets range from $4.50 to $4.50. On average, they anticipate the company's share price to reach $4.50 in the next year. This suggests a possible upside of 16.0% from the stock's current price. View analysts price targets for MOLN or view top-rated stocks among Wall Street analysts. How have MOLN shares performed in 2024? Molecular Partners' stock was trading at $4.18 at the beginning of 2024. Since then, MOLN shares have decreased by 7.2% and is now trading at $3.88. View the best growth stocks for 2024 here. When is Molecular Partners' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, May 10th 2024. View our MOLN earnings forecast. How were Molecular Partners' earnings last quarter? Molecular Partners AG (NASDAQ:MOLN) released its quarterly earnings data on Thursday, March, 14th. The company reported ($0.68) earnings per share (EPS) for the quarter. The business had revenue of $1.17 million for the quarter. Molecular Partners had a negative trailing twelve-month return on equity of 31.10% and a negative net margin of 885.11%. When did Molecular Partners IPO? Molecular Partners (MOLN) raised $81 million in an initial public offering (IPO) on Wednesday, June 16th 2021. The company issued 3,000,000 shares at $27.14 per share. J.P. Morgan, SVB Leerink, Cowen and RBC Capital Markets acted as the underwriters for the IPO and Kempen & Co. was co-manager. How do I buy shares of Molecular Partners? Shares of MOLN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:MOLN) was last updated on 4/24/2024 by MarketBeat.com Staff From Our PartnersThe #1 Biotech Stock to Have on Your Radar in 2024… Huge AlertsHe Is Giving Away BitcoinCrypto Swap ProfitsBitcoin Rockets To Record High But Buy THIS InsteadParadigm Presstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersFed launches fourth dollar overhaulStansberry ResearchThe #1 Crypto for 2024InvestorPlaceDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill Publishing Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Molecular Partners AG Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
